Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

This is the first and only perioperative immunotherapy approved to treat early gastric cancers

- PMLiVE

Odyssey Therapeutics appoints H Martin Seidel to Scientific Advisory Board

Seidel was previously Head of the Genomics Institute of the Novartis Research Foundation

- PMLiVE

MHRA approves Leqselvi for severe alopecia areata

Around 30% of patients saw 80% more scalp hair after 24 weeks of treatment

- PMLiVE

Athlone Laboratories hosts ministerial visit to discuss the future of critical medicines in Ireland

Minister Peter Burke, and representatives from IDA Ireland met with the company’s leadership team

- PMLiVE

Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education

See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.

Impetus Digital

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by US FDA for psoriatic arthritis

Sotyktu is the first TYK2 inhibitor approved for active psoriatic arthritis

- PMLiVE

Inizio Ignite announces key leadership appointments

The appointments have been announced amid team mergers

- PMLiVE

Commit Biologics appoints Thomas Montgomery Andresen as CEO

Andresen was CEO of T-Cypher Bio, an Oxford, UK-based immunotherapy company

- PMLiVE

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

- PMLiVE

Business as usual? Patient-centricity in the age of AI

By Nicolas Hall

- PMLiVE

Novo Nordisk elects employee representatives to Board of Directors

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026

- PMLiVE

Johnson & Johnson’s multiple myeloma treatment approved by US FDA

The approval was based on phase 3 data showing survival rates of 83.3% after three years

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links